Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.

Product Highlight - COSYREL

16 Sep 2020
  •  Cosyrel provides cardio-protection for your stable coronary artery disease patients.1
  •  Cosyrel gives 24-hour blood pressure control.2,3,4
  •  Cosyrel reduces pill burden and increases compliance in a single pill.5

References:
1. Bertrand, Michel E., et al. “Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.” American heart journal 170.6 (2015): 1092-1098.
2. Nedogoda, Sergey V., et al. “Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension.” Clinical drug investigation 33.8 (2013): 553-561.
3. Madej A., Buldak L., et al. “The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines.” Int J of Clin Pharmacology and Ther, vol. 47 – No. 11/2009 (686-694)
4. Madej A., Boldys A., et al. “Short-term antihypertensive therapy lowers the C-reactive protein level” Postepy Hig Med Dosw (online), 2012; 66:78-84
5. Gupta, Ajay K., Shazia Arshad, and Neil R. Poulter.  “Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis.” Hypertension 55.2 (2010): 399-407.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.